EHAVE INC News

EHAVE INC | 6-K: Report of foreign private issuer (related to financial reporting)

SECMay 21 16:18 ET · Announcements

Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics

Benzinga Real-time NewsFeb 3, 2023 12:47 ET

Ehave Provides Progress Update on Its HPPD Study With University of Melbourne

GlobeNewswireFeb 2, 2023 08:36 ET

FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder

Benzinga Real-time NewsDec 16, 2022 17:04 ET

Press Release: Ehave Shareholder From CEO Ben Kaplan and Corporate Update

Dow JonesDec 7, 2022 08:08 ET

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

Benzinga Real-time NewsJun 1, 2022 16:30 ET

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

GlobeNewswireJun 1, 2022 09:05 ET

Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM

Benzinga Real-time NewsMay 23, 2022 11:44 ET

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

GlobeNewswireApr 19, 2022 08:36 ET

KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area

Benzinga Real-time NewsFeb 15, 2022 15:32 ET

Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV

GlobeNewswireFeb 9, 2022 08:35 ET

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

GlobeNewswireDec 8, 2021 08:06 ET

Cannabis Movers & Shakers: Greenlight Distribution, Petalfast, Tinley Beverage, Shryne Group, Ehave, NY Cannabis Control Board

Benzinga Real-time NewsSep 25, 2021 21:15 ET

Press Release: Ehave Appoints Board-Certified Gastroenterologist And Licensed Physician Dr. Rahul Dixit To Its Medical Advisory Board

Dow Jones NewswiresSep 21, 2021 08:31 ET